Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avalo Therapeutics Inc

5.26
+0.22004.37%
Volume:13.05K
Turnover:67.30K
Market Cap:56.13M
PE:-0.25
High:5.29
Open:5.12
Low:5.00
Close:5.04
Loading ...

Avalo Therapeutics (AVTX) Has a New Rating from BTIG

TIPRANKS
·
31 Dec 2024

BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target

MT Newswires Live
·
19 Dec 2024

Avalo Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $40

THOMSON REUTERS
·
19 Dec 2024

Avalo Therapeutics Initiated at Buy by LUCID CAPITAL MARKETS

Dow Jones
·
17 Dec 2024

Avalo Therapeutics initiated with a Buy at Lucid Capital

TIPRANKS
·
17 Dec 2024

Avalo Therapeutics (AVTX) Is a Potential Hidden Gem With Significant Risk

TIPRANKS
·
09 Dec 2024

Avantium (AMS:AVTX) investors are sitting on a loss of 23% if they invested three years ago

Simply Wall St.
·
13 Nov 2024

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

GlobeNewswire
·
12 Nov 2024

Avalo Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Avalo Therapeutics Q3 2024 GAAP EPS $(2.83) Misses $(1.19) Estimate, Cash Position Of Approximately $82M With Subsequent Receipt Of Approximately $58M Of Warrant Exercise Proceeds In 4Q 2024, Provides Expected Runway Into At Least 2027

Benzinga
·
07 Nov 2024

BRIEF-Avalo Reports Third Quarter 2024 Financial Results And Recent Business Updates

Reuters
·
07 Nov 2024

Avalo Therapeutics Q3 Product Revenue USD 249 Thousand

THOMSON REUTERS
·
07 Nov 2024

Avalo Therapeutics: Cash and Cash Equivalents Were $81.9 Mln as of September 30, 2024

THOMSON REUTERS
·
07 Nov 2024

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

GlobeNewswire
·
07 Nov 2024